Resolving early cochlear inflammation prevents lasting damage from noise exposure

Area of Science:

• Ototolaryngology
• Pharmacology
• Neuroscience

Background:

• Noise-induced hearing loss (NIHL) is a significant global health issue with no current pharmacological treatments.
• Inflammation in the cochlea is a key factor in hearing loss, but targeting early inflammatory signals is not well understood.

Purpose of the Study:

• To identify novel pharmacological agents for preventing NIHL.
• To investigate the role of early inflammatory signaling in cochlear degeneration and explore therapeutic targets.

Main Methods:

• Phenotypic screening of quinoxaline derivatives in zebrafish.
• Mechanistic and functional validation using mouse models of acoustic trauma and permanent hearing loss.
• Analysis of NF-κB signaling pathways and cochlear inflammatory responses.

Main Results:

• Quinoxaline derivatives demonstrated otoprotective effects, preserving cochlear synapses and auditory function after noise exposure.
• One compound protected sensory hair cells in a permanent hearing loss model.
• Protection was linked to the attenuation of early NF-κB signaling and a shift towards a reparative inflammatory state.

Conclusions:

• Early NF-κB-dependent inflammatory signaling is a viable therapeutic target for NIHL.
• Quinoxaline derivatives represent promising candidates for pharmacological interventions against NIHL.
• A cross-species discovery approach is effective for identifying therapies that preserve sensory function by modulating early inflammatory pathways.